Novo Nordisk's Obesity Drug Study Allegedly Duped Investors
By Dorothy Atkins · January 27, 2025, 5:45 PM EST
Novo Nordisk was hit with a proposed securities class action in New Jersey federal court Friday, accusing the drugmaker of duping investors about its new weight loss drug CagriSema by failing...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login